Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis 2026
BriMind AI Score
ProprietaryScore based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals pioneered RNA interference therapeutics — drugs that silence the production of specific disease-causing proteins by degrading their messenger RNA. It has built a commercial portfolio in transthyretin amyloidosis and rare metabolic diseases, and its subcutaneous dosing schedules, in some cases only a few times a year, offer a meaningful convenience advantage over older treatment options.
How Alnylam Pharmaceuticals Makes Money
Revenue comes from marketed RNA interference products sold to specialist physicians treating rare and increasingly less-rare conditions, supplemented by collaboration revenue and royalties on partnered programmes. The commercial strategy centres on expanding from small rare-disease populations into larger indications — most importantly transthyretin amyloidosis with cardiomyopathy, which affects far more patients than the neuropathy indication that established the franchise.
Alnylam Pharmaceuticals Revenue & Profitability Breakdown
This chart shows how Alnylam Pharmaceuticals's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.
Key Financial Metrics
Alnylam Pharmaceuticals, Inc. trades at a trailing P/E of 43.32x, generates $271.5M in free cash flow, runs a debt/equity ratio of 220.62, and converts shareholder equity into profit at a 96.6% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.
Wall Street Analyst Consensus
Wall Street analysts covering Alnylam Pharmaceuticals, Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $371.35 (+60.2% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.
Intrinsic Value Estimates for ALNY
We use 3 valuation models to estimate ALNY's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.
Technical Price Signals
ALNY is currently in a death cross pattern, trading below its 50-day average of $255.36 and below its 200-day average of $317.18. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.
ALNY Investment Case: Bull vs Bear
ALNY's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.
Bull Case (Reasons to Buy)
- Expansion into transthyretin amyloid cardiomyopathy addresses a substantially larger patient population than the original rare-disease indications.
- Infrequent subcutaneous dosing is a genuine patient-preference advantage over treatments requiring frequent administration or infusion.
- A validated RNA interference platform can be redirected at many liver-expressed targets, providing a repeatable pipeline engine.
- Royalty and collaboration streams from partnered programmes provide revenue without commercial cost.
Bear Case (Key Risks)
- Competition in transthyretin amyloidosis is intense, including stabiliser drugs from large pharmaceutical companies and emerging gene editing approaches.
- Sustained profitability has been achieved only recently, so heavy commercial and research spending still constrains margins.
- RNA interference delivery remains largely limited to the liver, restricting the range of addressable diseases.
- Rare disease pricing faces increasing payer scrutiny and international reference pricing pressure.
What to Watch: ALNY Key Metrics
ALNY Stock — Frequently Asked Questions
Compare ALNY with Peers
More Healthcare Stock Analysis
In-depth reports on companies operating alongside ALNY — business models, bull and bear cases, and the metrics that matter.
Unlock the Full ALNY Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.